Tharimmune Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mark Wendland

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

Tharimmune And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Jan 23

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Feb 14

CEO

Mark Wendland (46 yo)

less than a year

Görev süresi

Mr. Mark Wendland is Chairman of the Board of Tharimmune, Inc. from February 5, 2026. Mr. Wendland is Chief Executive Officer & Director of Tharimmune, Inc. He was previously a Partner and Chief Operating...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Wendland	CEO & Chairman of the Board	less than a year	Veri yok	Veri yok
Mark Toomey	President	less than a year	Veri yok	Veri yok
Jacob Asbury	Chief Financial Officer	less than a year	Veri yok	Veri yok
Angela Radkowski	Chief Operating Officer	no data	Veri yok	Veri yok

0.2yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: THAR 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mark Wendland	CEO & Chairman of the Board	no data	Veri yok	Veri yok
Vaughn Smider	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jill Sommers	Director	no data	Veri yok	Veri yok
Gary Stetz	Independent Director	less than a year	Veri yok	0.26% $ 433.8k
Sireesh Appajosyula	Director	4.6yrs	US$791.16k	0.16% $ 274.6k
John Lambert	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Andreas Kremer	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Alan Bonder	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Vincent LoPriore	Director	less than a year	Veri yok	0% $ 0
Clay Kahler	Independent Director	less than a year	Veri yok	0% $ 0
William Wiley	Independent Director	no data	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: THAR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/02/13 20:01
Gün Sonu Hisse Fiyatı	2026/02/13 00:00
Kazançlar	2025/09/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Tharimmune, Inc. 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ashok Kumar	ThinkEquity LLC

Tharimmune Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Tharimmune, Inc. Announces Appointment of Angela Radkowski as Chief Operating Officer and Updates Board Committee Composition, Effective February 5, 2026

Tharimmune, Inc. Announces Board Appointments, Effective February 1, 2026

Less than half of directors are independent

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer, Effective December 12, 2025

High number of new directors

High number of new directors

Recent updates

Tharimmune, Inc. Announces Appointment of Angela Radkowski as Chief Operating Officer and Updates Board Committee Composition, Effective February 5, 2026

Tharimmune, Inc. Announces Board Appointments, Effective February 1, 2026

Less than half of directors are independent

Tharimmune And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization

Tharimmune, Inc. has completed a Follow-on Equity Offering in the amount of $54.8943 million.

Tharimmune Receives Non-Compliance Notice from Nasdaq

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer, Effective December 12, 2025

Tharimmune, Inc. Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Tharimmune, Inc. announced that it has received $544.997618 million in funding from a group of investors

Tharimmune, Inc. announced that it expects to receive $540 million in funding from a group of investors

Tharimmune, Inc. has filed a Follow-on Equity Offering in the amount of $5.349996 million.

New major risk - Share price stability

Tharimmune, Inc. has filed a Follow-on Equity Offering in the amount of $1.74 million.

High number of new directors

High number of new directors

Tharimmune, Inc Announces Board Changes, Effective from June 11, 2025

New major risk - Negative shareholders equity

New minor risk - Share price stability

Tharimmune, Inc. Announces Board and Committee Changes

Tharimmune, Inc., Annual General Meeting, Jun 10, 2025

Less than half of directors are independent

Tharimmune, Inc. Appoints Vincent Lopriore as Board Member

Tharimmune Receives A Non-Compliance Notice from the Listing Qualifications Staff of Nasdaq

Tharimmune, Inc. Announces Phase 2 Study Plan for TH104 in Patients with Moderate-To-Severe Pruritus Associated with Primary Biliary Cholangitis

Tharimmune, Inc. Presents Positive Clinical Data at AASLD Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune, Inc. (NasdaqCM:THAR) entered into a nonbinding, exclusive letter of intent to acquire Intract Pharma Ltd.

New major risk - Financial position

Tharimmune, Inc. Appoints David Jones to Its Scientific Advisory Board

Tharimmune, Inc. announced that it has received $2.084162 million in funding from GRAVITAS Capital Advisors, Inc., SDS Capital Group

Tharimmune, Inc. Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, Its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-To-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune Announces 1-for-15 Reverse Stock Split, Intends to Bring it into Compliance with Nasdaq's Minimum Bid Price Requirement for Continued Listing

Tharimmune, Inc., Annual General Meeting, May 14, 2024

Tharimmune, Inc. Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune, Inc. Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune, Inc. Announces Initiation of Phase 1 Clinical Trial of TH104

Tharimmune, Inc. Announces Positive Topline Data with Th104, Its Lead Candidate for Moderate-To-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune Reports Positive Phase 1 Data on Th104, Its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (Pbc)

Tharimmune Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tharimmune, Inc. has filed a Follow-on Equity Offering.

Hillstream Biopharma Progressing Towards Acquiring Clinical Stage Asset

New major risk - Shareholder dilution

Less than half of directors are independent

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2 HER3 Solid Tumors Via Bispecific and ADC Antibodies and Biologics

Hillstream Biopharma Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Hillstream BioPharma, Inc. announced delayed 10-Q filing

Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Is Hillstream BioPharma (NASDAQ:HILS) In A Good Position To Invest In Growth?

Hillstream BioPharma, Inc. Announces Initial Results Evaluating the Synergy

Hillstream BioPharma, Inc. Announces Acceptance of Abstract At AACR 2023 Annual Meeting Highlighting HSB-510 as Novel Bi-Functional Inhibitor for Solid Tumors & Leukemias

Hillstream BioPharma, Inc. to Host Virtual R&D Day to Showcase Its Emerging Immuno-Oncology Pipeline Targeting Drug-Resistant Cancers

Hillstream BioPharma Receives Non-Compliance Written Notice from the Nasdaq

Hillstream BioPharma, Inc., Annual General Meeting, Aug 08, 2022

Hillstream BioPharma, Inc. (NasdaqCM:HILS) announces an Equity Buyback for $1 million worth of its shares.

Hillstream BioPharma, Inc. announced delayed annual 10-K filing

Hillstream BioPharma, Inc. has completed an IPO in the amount of $15 million.

No independent directors

CEO

Liderlik Ekibi

Yönetim Kurulu Üyeleri

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları